These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20816509)

  • 1. Conducting chemoprevention clinical trials: challenges and solutions.
    Richmond E; O'Mara A
    Semin Oncol; 2010 Aug; 37(4):402-6. PubMed ID: 20816509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
    Moyad MA
    Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial.
    Hudmon KS; Love RR; Chamberlain RM
    J Cancer Educ; 1999; 14(2):83-7. PubMed ID: 10397482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
    Moyad MA
    Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohorts with familial disposition for colon cancers in chemoprevention trials.
    Burt RW
    J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
    Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
    J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of chemoprevention in cancer control.
    Greenwald P; Kelloff GJ
    IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future.
    Omenn GS
    Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer.
    Nayfield SG
    J Cell Biochem Suppl; 1996; 25():123-30. PubMed ID: 9027608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
    Lippman SM; Lee JJ
    Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What about chemoprevention for melanoma?
    Demierre MF
    Curr Opin Oncol; 2006 Mar; 18(2):180-4. PubMed ID: 16462188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.